Show simple item record

Determinación de respuesta inmune celular generada por péptidos sintéticos derivados de proteínas de Mycobacterium Tuberculosis H37rv

dc.contributor.advisorRodríguez Lancheros, Deisy Carolina
dc.contributor.advisorRodríguez Lancheros, Deisy Carolina
dc.contributor.advisorHernández Rojas, Edith Del Carmen
dc.contributor.authorTonguino Quiñonez, Erika Tatiana
dc.date.accessioned2022-03-10T14:13:23Z
dc.date.available2022-03-10T14:13:23Z
dc.date.issued2018
dc.identifier.urihttps://repositorio.universidadmayor.edu.co/handle/unicolmayor/4801
dc.description.abstractTeniendo en cuenta que la tuberculosis es una enfermedad infecciosa causada principalmente por el bacilo Mycobacterium tuberculosis, el cual infecta con mayor frecuencia los pulmones debido a que es transmitida por aerosoles (Tuberculosis pulmonar), además de afectar otros órganos (Tuberculosis extrapulmonar), y considerada después del SIDA como la segunda causa de muerte a nivel mundial, la Fundación Instituto de Inmunología de Colombia ha desarrollado una metodología lógica y racional para el diseño de vacunas sintéticas, la cual ha tenido éxito en estudios con malaria. Los avances obtenidos en el desarrollo de vacuna antituberculosa han permitido establecer péptidos de alta unión específica a células blanco (HABPs), que además inhiben la entrada de la micobacteria en ensayos in vitro, los cuales han sido postulados para estudios como posibles candidatos a vacuna. Dando continuidad a dicha metodología, en este proyecto mediante ensayos de linfoproliferación se evaluó parte de la respuesta inmune celular generada por péptidos sintéticos derivados de proteínas de Mycobacterium tuberculosis H37Rv ante PBMC de 8 individuos clasificados por prueba de QuantiFERON Qf (4Qf+ y 4Qf-), determinando que la mayoría de los péptidos sintéticos importantes en la interacción hospedero-patógeno no son inmunogénicos. Se estableció que los péptidos que hacen parte de las proteínas Rv0180c (31039), Rv2270 (37777) y Rv3494c (38373) estimulan la linfoproliferación de linfocitos de por lo menos 3 de los 4 individuos clasificados como Qf+, y a su vez que los resultados obtenidos contribuyen a una posible técnica de diagnóstico para diferenciar pacientes que hayan tenido contacto con M. tuberculosis de pacientes que nospa
dc.description.tableofcontentsRESUMEN 10 INTRODUCCIÓN 12 1. MARCO REFERENCIAL 15 1.1 Epidemiologia de la tuberculosis 15 1.2 Generalidades de la tuberculosis 16 1.2.1 El género Mycobacterium 16 1.2.2 Mycobacterium tuberculosis 18 1.2.3 Respuesta inmune ante M. tuberculosis 22 1.2.4 Diagnóstico de la enfermedad 25 1.2.4.1 Criterio clínico 25 1.2.4.2 Criterio bacteriológico 26 • Baciloscopia 26 • Cultivo bacteriano 27 1.2.4.3 Criterio radiológico 28 1.2.4.4 Criterio epidemiológico 29 1.2.4.5 Criterio tuberculínico 29 1.2.4.6 Criterio histopatológico 30 1.2.4.7 Ensayos de liberación de interferón gamma 30 1.2.5 Fármacos antituberculosos 31 1.2.6. Desarrollo de vacunas contra la tuberculosis 32 2. OBJETIVOS 36 2.1 General 36 2.2. Específicos 36 3. DISEÑO METODOLOGICO 37 3.1 Universo, Población, Muestra 37 3.2. Selección de péptidos 37 3.3 Obtención de muestras de sangre periférica 38 3.4 Separación de células mononucleares de sangre periférica (PBMC )38 3.5 Ensayos de Linfoproliferación 40 3.5.1 Ensayos preliminares utilizando MTT 40 3.5.2 Ensayos utilizando CFSE 42 3.5.3 Procesamiento y análisis de datos 44 4. RESULTADOS 45 4.1 Selección de péptidos 45 4.2 Obtención de PBMC 47 4.3 Ensayos de Linfoproliferación 47 4.3.1 Ensayos preliminares utilizando MTT 47 4.3.2 Ensayos utilizando CFSE 49 5. DISCUSIÓN 53 6. CONCLUSIONES 57 7. RECOMENDACIONES 58 8. BIBLIOGRAFIA 59spa
dc.format.extent68p.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad Colegio Mayor de Cundinamarcaspa
dc.rightsDerechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2018spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.titleDeterminación de respuesta inmune celular generada por péptidos sintéticos derivados de proteínas de Mycobacterium Tuberculosis H37rvspa
dc.typeTrabajo de grado - Pregradospa
dc.description.degreelevelPregradospa
dc.description.degreenameBacteriólogo(a) y Laboratorista Clínicospa
dc.identifier.barcode58423
dc.publisher.facultyFacultad de Ciencias de la Saludspa
dc.publisher.placeBogotá D.Cspa
dc.publisher.programBacteriología y Laboratorio Clínicospa
dc.relation.referencesKovacs-Simon A, Titball R, Michell SL. Lipoproteins of bacterial pathogens. Infection and immunity. 2011;79(2):548-61.spa
dc.relation.referencesWHO. Global Tuberculosis Report. Report. World Health Organization, 2017.spa
dc.relation.referencesEnfermedades CpeCylPdl. Factores de Riesgo de la Tuberculosis. 01-02-2018; Available from: https://www.cdc.gov/tb/esp/topic/basics/risk.htm.spa
dc.relation.referencesFine PE. Variation in protection by BCG: implications of and for heterologous immunity. The Lancet. 1995;346(8986):1339-45.spa
dc.relation.referencesEvans TG, Brennan MJ, Barker L, Thole J. Preventive vaccines for tuberculosis. Vaccine. 2013;31:B223-B6.spa
dc.relation.referencesLozano JM, Patarroyo ME. A rational strategy for a malarial vaccine development. Microbes and infection. 2007;9(6):751-60.spa
dc.relation.referencesPatarroyo ME, Patarroyo MA. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines. Accounts of chemical research. 2008;41(3):377-86.spa
dc.relation.referencesatarroyo M, Cifuentes G, Bermudez A, Patarroyo M. Strategies for developing multi‐ epitope, subunit‐based, chemically synthesized anti‐malarial vaccines. Journal of cellular and molecular medicine. 2008;12(5b):1915-35.spa
dc.relation.referencesPatarroyo ME, Cifuentes G, Martínez NL, Patarroyo MA. Atomic fidelity of subunitbased chemically-synthesized antimalarial vaccine components. Progress in biophysics and molecular biology. 2010;102(1):38-44.spa
dc.relation.referencesCifuentes G, Bermudez A, Rodriguez R, Patarroyo M, Patarroyo M. Shifting the polarity of some critical residues in malarial peptides' binding to host cells is a key factor in breaking conserved antigens' code of silence. Medicinal Chemistry. 2008;4(3):278-9spa
dc.relation.referencesOcampo M, Patarroyo MA, Vanegas M, Alba MP, Patarroyo ME. Functional, biochemical and 3D studies of Mycobacterium tuberculosis protein peptides for an effective anti-tuberculosis vaccine. Critical reviews in microbiology. 2014;40(2):117-45.spa
dc.relation.referencesDorronsoro I, Torroba L, editors. Microbiología de la tuberculosis. Anales del sistema sanitario de Navarra; 2007: SciELO Espana.spa
dc.relation.referencesario de Navarra; 2007: SciELO Espana. 13. Chan VL. Bacterial genomes and infectious diseases. Pediatric research. 2003;54(1):1-7.spa
dc.relation.referencesGarcía JG, Gutiérrez JP, Antuña AS. Respiratory infections caused by environmental mycobacteria. 2005 [cited 41 4]; 206-19]. Available from: http://www.aeras.org/annualreport2016.spa
dc.relation.referencesL. B. The Basic of Clinical Bacteriology. In: Palomino JC CLS, Ritacco V Editors, editor. 2007;Tuberculosis 2007: From basic science to patient care 2007.spa
dc.relation.referencesKaur D, Guerin ME, Škovierová H, Brennan PJ, Jackson M. Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. Advances in applied microbiology. 2009;69:23-78spa
dc.relation.referencesGonzalo-A.Jesus MD, Martin Carlos and Aguilo Nacho. MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic. 2017.spa
dc.relation.referencesBrennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis. 2003;83(1):91-7.spa
dc.relation.referencesTrabajo INdSeHee. Mycobacterium tuberculosis: viabilidad, propagación y transmisión Instituto Nacional de Seguridad e Higiene en el Trabajo, 23 de Septiembre de 2012spa
dc.relation.referencesKaufmann SH. How can immunology contribute to the control of tuberculosis? Nature reviews Immunology. 2001;1(1):20.spa
dc.relation.referencesCosma CL, Sherman DR, Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annual Reviews in Microbiology. 2003;57(1):641-76.spa
dc.relation.referencesGarcıá -Pérez BE, Mondragón-Flores R, Luna-Herrera J. Internalization of Mycobacterium tuberculosis by macropinocytosis in non-phagocytic cells. Microbial pathogenesis. 2003;35(2):49-55spa
dc.relation.referencesRussell DG. Who puts the tubercle in tuberculosis? Nature Reviews Microbiology. 2007;5(1):39.spa
dc.relation.referencesKaufmann SH, Hussey G, Lambert P-H. New vaccines for tuberculosis. The Lancet. 2010;375(9731):2110-9spa
dc.relation.referencesSchaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nature medicine. 2003;9(8):1039spa
dc.relation.referencesFigueroa MCEG-S. Respuesta Inmune a la infección por Mycobacterium tuberculosis. Una revisión de la literatura. Rev Inst Nal Enf Resp Mex. 2001;14(2):114-28.spa
dc.relation.referencesGoicochea CR, Castillo SB, Tarazona PC, Narvaez CC, Última JC, Última RC, et al. Asociación de criterios de Stegen modificado por Toledo para el diagnóstico de tuberculosis pediátrica, Hospital Belén de Trujillo. UCV-SCIENTIA. 2015;4(1):64-71.spa
dc.relation.referencesTincopa Wong OW, Castro L, Lelie K, Plasencia Angulo WF, Valverde López JC. Tuberculosis cutánea: Rasgos clínicos, histopatológicos y epidemiológicos en un Hospital General de Trujillo, Perú. Dermatol peru. 2006;16(3):220-32.spa
dc.relation.referencesAbbate E, Vescovo M, Natiello M, Cufré M, García A, Ambroggi M, et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacables epidemiológicos, bacteriológicos, terapéuticos y evolutivo. 2007spa
dc.relation.referencesCavanaugh JS, Shah NS, Cain KP, Winston CA. Survival among Patients with HIV Infection and Smear-Negative Pulmonary Tuberculosis-United States, 1993–2006. PLoS One. 2012;7(10):e47855spa
dc.relation.referencesArteaga Arteaga A, Vélez Moncada E, Salazar Blanco OF, Morales Múnera OL, Cornejo Ochoa JW, Valencia Pino DC. Clinical and sociodemographic characteristics of children, younger than 13 years, with or without a confirmed diagnosis of pulmonary tuberculosis, at Hospital Universitario San Vicente de Paúl, Medellín, Colombia, 2007-2008. Iatreia. 2010;23(3):227-39.spa
dc.relation.referencesAbbate EH, Palmero DJ, Castagnino J, Cufre M, Doval A, Estevan R, et al. Tratamiento de la tuberculosis: Guía práctica elaborada por la Sección Tuberculosis, Asociación Argentina de Medicina Respiratoria. Medicina (Buenos Aires). 2007;67(3):295- 305spa
dc.relation.referencesGarzón MC, Angée DY, Llerena C, Orjuela DL, Victoria JE. Vigilancia de la resistencia del Mycobacterium tuberculosis a los fármacos antituberculosos, Colombia 2004-2005. Biomédica. 2008;28(3):319-26spa
dc.relation.referencesArias Guillén M, Palomar R, Arias M. Avances en el diagnóstico de la infección tuberculosa latente en pacientes en tratamiento renal sustitutivo. Nefrología (Madrid). 2011;31(2):137-41.spa
dc.relation.referencesCardoso EM. Multiple drug resistance: a threat for tuberculosis control. Revista Panamericana de Salud Pública. 2004;16(1):68-73.spa
dc.relation.referencesRamakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nature reviews Immunology. 2012;12(5):352.spa
dc.relation.referencesMoliva JI, Turner J, Torrelles JB. Prospects in Mycobacterium bovis Bacille Calmette et Guerin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? Vaccine. 2015;33(39):5035-41spa
dc.relation.referencesAERAS. GLOBAL CLINICAL PIPELINE OF TB VACCINE CANDIDATES.Information is self-reported by vaccine sponsors. 26/2017. Available from: http://www.aeras.org/annualreport2016.spa
dc.relation.referencesAgger EM, Cassidy JP, Brady J, Korsholm KS, Vingsbo‐Lundberg C, Andersen P. Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology. 2008;124(2):175-85.spa
dc.relation.referencesPetrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunology and cell biology. 2004;82(5):488.spa
dc.relation.referencesCole S, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Erratum: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;396(6707):190spa
dc.relation.referencesSong H, Sandie R, Wang Y, Andrade-Navarro MA, Niederweis M. Identification of outer membrane proteins of Mycobacterium tuberculosis. Tuberculosis. 2008;88(6):526-44.spa
dc.relation.referencesVizcaíno C, Restrepo-Montoya D, Rodríguez D, Niño LF, Ocampo M, Vanegas M, et al. Computational prediction and experimental assessment of secreted/surface proteins from Mycobacterium tuberculosis H37Rv. PLoS computational biology. 2010;6(6):e1000824spa
dc.relation.referencesPatarroyo MA, Curtidor H, Plaza DF, Ocampo M, Reyes C, Saboya O, et al. Peptides derived from the Mycobacterium tuberculosis Rv1490 surface protein implicated in inhibition of epithelial cell entry: Potential vaccine candidates? Vaccine. 2008;26(34):4387-95.spa
dc.relation.referencesOcampo M, Aristizábal-Ramírez D, Rodríguez DM, Muñoz M, Curtidor H, Vanegas M, et al. The role of Mycobacterium tuberculosis Rv3166c protein-derived high-activity binding peptides in inhibiting invasion of human cell lines. Protein Engineering, Design & Selection. 2012;25(5):235-42.spa
dc.relation.referencesForero M, Puentes A, Cortés J, Castillo F, Vera R, Rodríguez LE, et al. Identifying putative Mycobacterium tuberculosis Rv2004c protein sequences that bind specifically to U937 macrophages and A549 epithelial cells. Protein science. 2005;14(11):2767-80.spa
dc.relation.referencesRodríguez DC, Ocampo M, Reyes C, Arévalo‐Pinzón G, Munoz M, Patarroyo MA, et al. Cell‐Peptide Specific Interaction Can Inhibit Mycobacterium tuberculosis H37Rv Infection. Journal of cellular biochemistry. 2016;117(4):946-58.spa
dc.relation.referencesOcampo M, Curtidor H, Vanegas M, Patarroyo MA, Patarroyo ME. Specific Interaction between Mycobacterium tuberculosis Lipoprotein‐derived Peptides and Target Cells Inhibits Mycobacterial Entry In Vitro. Chemical biology & drug design. 2014;84(6):626-spa
dc.relation.referencesPlaza DF, Curtidor H, Patarroyo MA, Chapeton‐Montes JA, Reyes C, Barreto J, et al. The Mycobacterium tuberculosis membrane protein Rv2560− biochemical and functional studies. The FEBS journal. 2007;274(24):6352-64.spa
dc.relation.referencesThe FEBS journal. 2007;274(24):6352-64. 50. Rodríguez DC, Ocampo M, Varela Y, Curtidor H, Patarroyo MA, Patarroyo ME. Mce4F Mycobacterium tuberculosis protein peptides can inhibit invasion of human cell lines. Pathogens and disease. 2015;73(3)spa
dc.relation.referencesRodríguez DM, Ocampo M, Curtidor H, Vanegas M, Patarroyo ME, Patarroyo MA. Mycobacterium tuberculosis surface protein Rv0227c contains high activity binding peptides which inhibit cell invasion. Peptides. 2012;38(2):208-16spa
dc.relation.referencesRodríguez D, Vizcaíno C, Ocampo M, Curtidor H, Pinto M, Elkin Patarroyo M, et al. Peptides from the Mycobacterium tuberculosis Rv1980c protein involved in human cell infection: insights into new synthetic subunit vaccine candidates. Biological chemistry. 2010;391(2/3):207-17spa
dc.relation.referencesProfile BSD, Workstation BO, Controller BB, Controller BAS, Sensor BS. Product description. Migration. 2011;3:4.spa
dc.relation.referencesBøyum A. Separation of white blood cells. Nature. 1964;204(4960):793-4.spa
dc.relation.referencesProfile BSD, Workstation BO, Controller BB, Controller BAS, Sensor BS. Product description. Migration2011. p. 4.spa
dc.relation.referencesDenizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of immunological methods. 1986;89(2):271-7.spa
dc.relation.referencesParish CR, Glidden MH, Quah BJ, Warren HS. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Current protocols in immunology. 2009:4.9. 1-4.9. 13.spa
dc.relation.referencesQuah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nature protocols. 2007;2(9):2049.spa
dc.relation.referencesMartinez P, Lopez C, Saravia C, Vanegas M, Patarroyo MA. Evaluation of the antigenicity of universal epitopes from PvDBPII in individuals exposed to Plasmodium vivax malaria. Microbes and infection. 2010;12(14-15):1188-97.spa
dc.relation.referencesArenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends in immunology. 2015;36(12):763-77spa
dc.relation.referencesRevelen R, D Arbonneau F, Guillevin L, Bordron A, Youinou P, Dueymes M. Comparison of cell-ELISA, flow cytometry and Western blotting for the detection of antiendothelial cell antibodies. Clinical and experimental rheumatology. 2002;20(1):19-26.spa
dc.relation.referencesNguyen XD, Eichler H, Dugrillon A, Piechaczek C, Braun M, Klüter H. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. Journal of immunological methods. 2003;275(1-2):57-68.spa
dc.relation.referencesBehr MA. Comparative genomics of mycobacteria: some answers, yet more new questions. Cold Spring Harbor perspectives in medicine. 2015;5(2):a021204.spa
dc.relation.referencesCáceres SM, Ocampo M, Arévalo-Pinzón G, Jimenez RA, Patarroyo ME, Patarroyo MA. The Mycobacterium tuberculosis membrane protein Rv0180c: evaluation of peptide sequences implicated in mycobacterial invasion of two human cell lines. Peptides. 2011;32(1):1-10.spa
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessspa
dc.rights.creativecommonsAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)spa
dc.subject.proposalTuberculosisspa
dc.subject.proposalMycobacterium tuberculosis H37Rvspa
dc.subject.proposalPéptidos sintéticosspa
dc.subject.proposalHABPsspa
dc.subject.proposalPBMCspa
dc.subject.proposalInfoproliferaciónspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.redcolhttps://purl.org/redcol/resource_type/TPspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.coarhttp://purl.org/coar/access_right/c_14cbspa


Files in this item

Thumbnail
Name:
Escrito Final Tesis Erika ...
Size:
2.668Mb
Format:
PDF
View/Open
Thumbnail
Name:
Escrito Final Tesis Erika Tonguino ...
Size:
219.7Kb
Format:
PDF
View/Open
Thumbnail
Name:
Sustentacion Erika Tonguino.pdf
Size:
4.417Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2018
Except where otherwise noted, this item's license is described as Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2018